Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy

Cancer advocacy and fundraising in Nigeria

ASCO 2024: Lung cancer roundup

Teclistamab continues to demonstrate deep and durable responses in relapsed/refractory multiple myeloma

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer

ASCO 2024: Highlights and analysis

ASCO 2024: Advances in NSCLC

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma

Immune therapy with belantamab mafodotin and elotuzumab shows encouraging safety profile and preliminary efficacy in RRMM

Osimertinib success in locally advanced EGFR-mutated NSCLC

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients